References
- Bonner T. I., Buckley N. J., Young A., Brann M. R. Identification of a family of muscarinic receptor genes. Science 1987; 237: 527–532
- Wallis R. M., Burges R. A., Cross P. E., MacKenzie A. R. Darifenacin, a selective M3 antagonist. J. Pharmacol. Res. 1995; 31S: 54
- Nunn P. A., Greengrass P. M., Newgreen D. T., Naylor A. M., Wallis R. M. The binding profile of the novel muscarinic receptor antagonist darifenacin, against the five cloned human muscarinic receptors expressed in CHO Cells. Brit. J. Pharmacol Proceedings of Brighton Meeting. 1996
- Buckley N. J., Bonner T., Buckley C. M., Brann M. R. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol. Pharmacol. 1989; 35: 469–476
- Hill A. V. The possible effects of the aggregation of the molecules of haemoglobin on the dissociation curve. J. Physiol. 1910; 40: iv–vii
- Cheng Y. C., Prusoff W. H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol. 1973; 22: 3099–3108
- Dörje F., Wess J., Lambrecht G., Tacke R., Mutschler E., Brann M. R. Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J. Pharmacol. Exp. Ther. 1991; 256: 727–733
- Birdsall N. J., Burgen E. C., Hulme E. C., Wells. The effects of ions on the binding of agonists and antagonists to muscarinic receptors Br. J. Pharmacol. 1979; 67: 371–377
- Hulme E. C., Birdsall N. J. M., Buckley N. J. Muscarinic receptor subtypes. Annu. Rev. Pharmacol. Toxicol. 1990; 30: 633–73